Lacosamide induced Brugada I morphology in the setting of septicemia: A case report

Medicine (Baltimore). 2021 May 7;100(18):e25577. doi: 10.1097/MD.0000000000025577.

Abstract

Introduction: Brugada syndrome may be unmasked by non-antiarrhythmic pharmaceuticals or drugs. Lacosamide is an antiepileptic agent with a novel mechanism of sodium channel inhibition and has the potential to cause cardiac sodium channel blockade.

Patient concerns: In this report, we describe the case of patient with a history of a seizure disorder who presented with Brugada I electrocardiogram morphology in the setting of septicemia.

Diagnosis: Brugada I electrocardiogram morphology was unmasked by lacosamide antiepileptic monotherapy.

Interventions: Lacosamide therapy was discontinued.

Outcomes: Normalization of the electrocardiogram and resolution of Brugada morphology occurred on hospital day 1.

Conclusion: Caution should be exercised in the use of lacosamide in those at risk for conduction delay, or in combination therapy with medications that impair renal clearance, metabolism of lacosamide, or that display inherent sodium channel blocking properties.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Anticonvulsants / adverse effects*
  • Anticonvulsants / pharmacokinetics
  • Brugada Syndrome / chemically induced*
  • Brugada Syndrome / diagnosis
  • Electrocardiography
  • Epilepsy / drug therapy*
  • Humans
  • Lacosamide / adverse effects*
  • Lacosamide / pharmacokinetics
  • Male
  • Renal Elimination / physiology
  • Sepsis / complications*
  • Sepsis / physiopathology
  • Voltage-Gated Sodium Channel Blockers / adverse effects*
  • Voltage-Gated Sodium Channel Blockers / pharmacokinetics

Substances

  • Anticonvulsants
  • Voltage-Gated Sodium Channel Blockers
  • Lacosamide